Received: 4 June 2021

Revised: 31 August 2021



```
WILEY
```

Changes in glucagon-like peptide 1 and 2 levels in people with obesity after a diet-induced weight-loss intervention are related to a specific microbiota signature: A prospective cohort study

Dear Editor,

Glucagon-like peptide (GLP)-1 and -2 are enteroendocrine hormones released postprandially to regulate glucose metabolism.^{1,2} For reasons that are unclear, GLP-1/2 secretion is impaired in obesity.³ The enteroendocrine system has been linked to gut microbiota,⁴ but whether this could be affected by obesity-induced dysbiosis is unknown. Here, we investigated the relationship between GLP dynamics and gut microbiota in a prospective cohort of patients with obesity enrolled in a 6-month restrictive diet interventional weight-loss trial (trial registration number ISRCTN12973246), where effective weight loss (\geq 10%) was achieved at the end of the follow-up. We determined the association between GLP secretion in response to nutrient ingestion and specific metagenomic signatures using taxonomic profiling and functional analysis.

The main characteristics of the cohort are described in Table S1. Patients showed improvement in glucose and lipid profiles at 6 months. Notably, fasting GLP-1/2 levels were significantly lower after weight loss, with a trend for improved GLP response to a meal tolerance test (MTT). The intervention had no significant impact on intra-community (alpha) diversity measured by species richness or evenness (Figure S1), in agreement with other reports.^{5–7} Nonetheless, a higher alpha diversity was observed in patients with lower plasma urate levels, lower systolic blood pressure, and lower weight (p = 0.008, 0.026, and 0.04, respectively), all related to a "healthy" metabolic status. No differences were found in inter-community (beta) diversity, as estimated by the Bray-Curtis distance (p = 0.216), or when microbial populations at different taxonomic levels were compared before and after the intervention (Figure 1A). Remarkably, the unique patient identifier variable correlated with all tested principal components (Figure S2), pointing to individual variation as the

main driver of the data variability. Accordingly, we rejected the hypothesis of microbial composition independence among pre- and post-intervention observations from the same patient, which stresses the importance of accounting for a paired data setting in the downstream analysis (results obtained at family taxonomic level, Figure 1B).

Association analysis of clinical parameters and gut microbiota revealed several significant associations between different bacterial families and body mass index, HOMA-IR, and/or plasma urates (Figure 1C).

Fasting GLP-1/2 levels were inversely related to Spirochaetaceae, Peptostreptococcaceae, Clostridiaceae, Ruminococcaceae, Erysipelotrichaceae, Eubacteriaceae, and Lachnospiraceae, and positively related to Prevotellaceae, Acidaminococaeae, Selenomonadaceae, Coriobacteriaceae, Veillonelaceae, Odoribacteriaceae, Bacteriodaceae, Rikenellaceae, Porphyromonadaceae, Desulfovibrionaceae, and Sutterellaceae. Notably, we found a contrasting correlation pattern for GLP-1/2 response in the MTT, as Spirochaetaceae showed a significant positive correlation with GLP-1 response, whereas the GLP-2 response was negatively correlated with Acidaminococcaceae, Desulfovibrionaceae, and Sutterellaceae (Figure 1C).

To address the statistical sparsity issues and the lack of homogeneously distributed variables among individuals (common to microbiome data analysis), we applied the FitZig mixture model,⁸ which allows for discrimination of taxonomic difference abundances between the study groups. Differential abundance analysis pre-/postintervention revealed more than 40 species or genera with a significant variation in terms of fold-change and statistical relevance when considered simultaneously (Figure S3). Abundance ranking analysis revealed noteworthy interindividual variations, suggesting that communities

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2021} The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics



FIGURE 1 Taxonomy composition of the study population. (A) Comparison of relative abundances of different taxa at the family level between post-intervention (outerchart) and basal (inner chart) faecal microbiota, showing no significant differences. (B) Individual variability between basal (B) and post-intervention (6 M). The presence of different microorganisms is indicated by colours; the same colour indicates the same family. Microbial taxa are based on the family level. Significant differences were observed for each individual after diet intervention (*p*-value < 0.05). The chi-square test was used for analysis (n = 18 classified as basal (B) and post-intervention (6 M)). (C) Associations of gut microbiota with clinical variables and intestinal hormones. Heatmap depicting Spearman's rank correlation coefficient of the relative abundances at the family level of different gut microbiota and clinical variables and incretin hormones in all individuals. For correlational studies, all gathered data (basal and 6 months) are included in the analysis. Adjusted *p*-values: #padj < 0.25; *padj < 0.05. Peptostreptococcaceae, Clostridiaceae, Ruminococcaceae, Oscillospiraceae, Eubacteriaceae, and Lachnospiraceae showed negative associations with BMI, HOMA-IR index, and/or plasma urates. By contrast, Streptococcaceae, Prevotellaceae, Selenomonadaceae, Coriobacteriaceae, Rakenellaceae, Porphyromonadaceae, and Sutterellaceae showed positive associations with the afore mentioned parameters. Odoribacteriaceae showed a negative association with body mass index (BMI) and a positive association with plasma urates

-1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0

1

					1	1			1			
Dhadaasiiillaasaa		FC										
Rnodospiriliaceae	Azospirillum sp. 51 20		۱٢									
	Azospirillum sp. CAG:239		Π									
Clastridiagaaa	Azospirillum sp. 47_25		11									
Clostitulaceae	Clostridium sp. CAG:349	-	11									
	Clostridium sp. CAG:571		П									#
	Clostridium sp. CAG:440		П									#
	Clostridium sp. CAG:575											#
	Clostridium sp. CAG:27_14											#
	Clostridium sp. CAG:921		Ш									#
	Clostridium sp. CAG:452		Ш									#
	Clostridium sp. CAG:465		II				_					#
	Clostridium sp. CAG:567		П									#
	Clostridium sp. CAG:508		II									#
	Clostridium sp. CAG:798		II									#
	Clostridium sp. CAG:780		II									#
	Clostridium sp. CAG:75		П		#		#	#		#		
	Clostridium sp. CAG:42_12		11				#	#				
	Clostridium sp. CAG:230		I	#	#	#						
	Clostridium sp. L2-50		II				#					#
	Clostridium sp. CAG:127				*		#					#
	Clostridium sp. CAG:492		II			_					_	
Proteobacteria_uc	Clostridium sp. CAG:343	_	II									#
Prevotellaceae	Proteobacteria_uc	_	11					1				
	Paraprevotellauc		II									
	Proteobacteria clara CAG:116		II									
Enterobacteriaceae	Proteobacteria sp. CAG:873	_	II								*	
	Escherichia coli						#					
Porphyromonadaceae		-					#					
Selenomonadaceae		-						4			ш	
	Mitsuokella_uc Mitsuokella multacida		II		•	#	# #	*		#	# #	
	Selenomonadaceae_uc					4	#				#	
Acidaminococcaceae	Phascolarctobacterium sp. CAG:266	-				#		#		_		
Pasteurellaceae	Haemophilus uc		11				#				_	#
Lacnnospiraceae	Butvrivibrio crossotus	-					#					
	Butyrivibrio_uc		11									
	Butyrivibrio crossotus CAG:259		11									
	Lachnospiraceae bacterium 6_1_63FAA		II									
Eubacteriaceae	Lachnospiraceae bacterium 5_1_63FAA		ll		#	#	#					
	Eubacterium sp. CAG:202	-	[[#	#		#		
	Eubacterium sp. CAG:274		II									
Odoribacteraceae	Eubacterium sp. CAG:192		ll									#
Eggerthellaceae	Odoribacter laneus CAG:561											
Bacteroidaceae	Cryptobacterium sp. CAG:338											
	Bacteroides plebeius CAG:211											
Veillonellaceae	Bacteroides plebeius	_										
	Veillonella sp: CAG:933		۱L	500								
		-303	3	onse	orse	a'	222	Silling Street	LOS [®]	A.	an an	A Solo
		1	100	, ,	esq in		ing.	4.	Ch X	5		5.
		S.V		GR.V	400	48						

from the same individual were generally more similar to one and other than to those of other individuals, with individual variability more important than diet–responsive variation (Figure 1B). These results are in line with previous studies showing that human gut microbiota response to diet has a strong individuality and indicating that the effects of the diet per se as the main source of variability are markedly diminished, which is the opposite to that described in mice.^{9,10}

Most of the significantly increased taxa at followup belonged to the Clostridiaceae family, specifically the genus Clostridium (Figure 2). Analysis of GLP-1/2 dynamics revealed a positive association between Mitsuokuella_uc and fasting GLP-1/2 levels, but a significant negative association between Mitsuokuella_uc and GLP-2 response in the MTT. Contrastingly, Clostridium sp. CAG:75, CAG:230, and CAG:127 and Lachnospiraceae bacterium 5 1 63FAA (which all increased after the weight loss intervention) correlated negatively with fasting levels of GLP-2 but positively with its response in the MTT. Of note, Clostridium sp. CAG:127 showed a significant positive correlation with GLP-2 response. Similarly, Clostridium sp. CAG: 230 correlated negatively with fasting GLP-1 but positively with GLP-1 response in the MTT (Figure 2). Overall, the data indicate that fasting levels of GLPs are inversely related to their response to the MTT, with higher levels signalling poor responsiveness. Notably, this behaviour, which differed for GLP-1 and GLP-2 was, at least in part, associated with a specific microbiota signature.

The study at functional gene level identified significant associations between the expression of non redundant genes aligned in the KEGG database. A total of 116 genes were found to be statistically significant, however, only 54 of them could be identified and were distributed into different biologically relevant functions (Table S2).

Hierarchical clustering of the correlation data matrix between genes and taxonomy at the gene level revealed the presence of two highly populated clusters (Figure 3A). Remarkably, except for *Lachnospiraceae bacterium* 5_1_63FAA, those species that increased in abundance after the intervention and were positively associated with GLPs response (*Clostridium* sp. CAG:75, *Clostridium* sp. CAG:127, *Clostridium* sp. CAG: 230) had similar gene association patterns. These patterns contrasted with those for *Mitsuokella_uc*, whose abundance decreased at follow-up and inversely correlated with GLP response. Only a minor fraction of the total studied genes (12%, seven genes) could be projected onto a metabolic map (Figure 3B), indicating that most of the altered genes have other biological functions. Indeed, no particular pathway was enriched, suggesting a global modulation of gut microbiota in terms of metabolism.

Our results lead us to consider that while diet-induced weight loss impacts gut microbiota composition, and the global metabolic regulation of microbial community interactions maintains a balanced ecosystem. This would agree with the plasticity of gut microbiota, allowing rapid adaption to environmental changes. In conclusion, our study shows that GLP secretion, which is dependent on body weight and metabolic status, is linked to specific gut microbiota. Further mechanistic studies are warranted to understand how gut microbiota regulate GLP secretion and whether those bacterial strains associated with GLP dynamics might represent novel probiotic approaches to restore host mucosal GLP response in obesity.

ACKNOWLEDGMENTS

The study was supported by grants from the Instituto de Salud Carlos III (PI14/00228, PI17/0153 and PI20/00338 to J.V.), Ministerio de Ciencia e Innovación (RTI2018-093919-B-I00 to S.F.-V. and PID2019-105969GB-I00 to A.M) and Generalitat Valenciana (PROMETEO/2018/A/133 to A.M), co-financed by the European Regional Development Fund. The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CB07708/0012) is an initiative of the Instituto de Salud Carlos III. S.F-V. acknowledges the Miguel Servet tenure-track program (CP10/00438 and CPII16/00008) from Fondo de Investigación Sanitaria. We would like to acknowledge the patients for participating in the study, and the BioBank IISPV (PT17/0015/0029) integrated into the Spanish National Biobanks Network for its collaboration. IISPV is a CERCA institution.

FIGURE 2 Diet-induced microbiota changes and associations between species and variables related to metabolic health status. Log fold-change (FC) and Spearman correlation analyses of the relative abundance at the species level of gut microbiota and clinical variables and incretin hormones in all individuals. For FC analysis, a zero-inflated Gaussian mixture model (fitZig) from the metagenomeSeq R package was used, contrasting 6 M/basal. The subject factor in the patient identifier variable (IDPAT) is used as a batch effect, as the inter-individual differences in the microbiota were greater than the changes caused by the diet. As a consequence, the IDPAT variable was introduced as an adjusting covariate in the model to investigate diet-induced changes after the 6-month weight-loss program. Spearman correlation analysis revealed a negative correlation between most of the *Clostridium* species, *Hemophilus_*uc, and *Eubacterium* sp. CAG 192 and plasma urates, whereas *Clostridium* sp. CAG:75 and *Eubacterium* sp. CAG 202 were negatively correlated with HOMA-IR index. *Proteobacteria* sp. CAG:873 and *Mitsuokella multocida*, showed a significant positive correlation with body mass index (BMI) and HOMA-IR, respectively. All padj < 0.005 in FC and #padj < 0.25; *padj < 0.05 for Spearman correlation analyses



CONFLICT OF INTEREST

The authors declare no conflict of interest.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All participants gave their informed consent, and the study was reviewed and approved by the ethics and research committee of University Hospital Joan XXIII from Tarragona, Spain.

AUTHOR CONTRIBUTIONS

M-Mar Rodríguez-Peña, Gemma Llauradó, and Brenno Astiarraga participated in the sample processing, functional studies, laboratory determinations, and statistical analysis. M-Mar Rodríguez-Peña, Jesus Seco, Brenno Astiarraga, and Victoria Ceperuelo-Mallafré wrote the manuscript. Jesus Seco, Adrià Caballé, Camille Stephan-Otto Attolini, and Vicente Pérez-Brocal performed statistical analysis of taxonomical and clinical features. Andrés Moya and Ana Megía provided scientific discussion and revised the manuscript. Silvia Pellitero and Núria Vilarrasa participated in the human sample recruitment and conducted the clinical trial. Joan Vendrell and Sonia Fernández-Veledo conceived, designed, and supervised the research project and wrote the manuscript. Joan Vendrell and Sonia Fernández-Veledo are also the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article and its Supplementary Information. Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding authors. The metagenome data sets from this study are available in the EBI Short Read Archive under the study accession PRJEB43147, with accession numbers [ERX5107074 – ERX5107109].

FUNDING INFORMATION

Instituto de Salud Carlos III, Grant Numbers: PI14/00228, PI17/0153 and PI20/00338; Ministerio de Ciencia e Innovación, Grant Numbers: RTI2018-093919-B-I00 and PID2019-105969GB-I00; Generalitat Valenciana, Grant Number: PROMETEO/2018/A/133.

> M-Mar Rodríguez-Peña^{1,2} Brenno Astiarraga^{1,3} Jesus Seco¹ Victoria Ceperuelo-Mallafré^{1,3} Adrià Caballé⁴ Vicente Pérez-Brocal^{5,6} Camille Stephan-Otto Attolini⁴ Andrés Moya^{5,6,7} Gemma Llauradó^{2,8} Ana Megía^{1,2} Silvia Pellitero⁹ Núria Vilarrasa^{2,10} Sonia Fernández-Veledo^{1,2}

¹ Endocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain ² CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain ³ Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Tarragona, Spain

FIGURE 3 Spearman correlation analysis of microbiota species and metabolic bacterial function for a set of 45 genes. (A) Hierarchical clustering of the correlation data matrix was conducted at the gene level, which revealed the presence of two highly populated clusters (labelled as 1 and 2). Annotation of metabolic pathways according to the KEGG database, sorted in alphabetical order: [C]: energy production and conversion; [E]: amino acid transport and metabolism; [G]: carbohydrate transport and metabolism; [H]: coenzyme transport and metabolism; [J]: translation; ribosomal structure and biogenesis; [K]: transcription; [L]: replication, recombination, and repair; [M]: cell wall/membrane/envelope biogenesis; [O]: post-translational modification; protein turnover, chaperones; [P]: inorganic ion transport and metabolism; [T]: signal transduction mechanism; [U|W]: intracellular trafficking and vesicular transport; [V]: defence mechanism. Correlations where an associated p-adjusted value was greater than 0.25 were neglected for additional analysis. Genes associated with replication, recombination, and repair (encoded as [L]), such as MobA/MobB, site-specific recombinases, integrases, and transposases, were found to positively correlate with an increase in the presence of Clostridium species. A similar pattern was found (with an equivalent number of enzymes, 4) with post-translational modification enzymes ([O]) and enzymes involved in signal transduction ([T]). An increase in the abundance of the metabolic enzymes glycosyltransferase 36, dicarboxylate transporter, and carbohydrate-solute binding proteins were positively correlated with Clostridiaceae family members. Genes associated with amino-acid transport and metabolism ([E]) and inorganic ion transport ([P]), such as branched-amino acid transporter and ABC-related transporter, were also modified. (B) Gene projection of statistically relevant enzyme subset on a KEGG-modified metabolic enzyme pathway. This analysis revealed only a minor fraction of the total studied genes (12%, seven genes) that could be projected into a metabolic map constellation: Aln-; Gln-t-RNA synthase ([J]), PALM hydrolase ([L]), nicotinate-phosphoribosyltransferase ([H]), N-acetylmuranoyl-l-alanine amidase ([M]), glycerol-phosphoryl-diester-phospho-diesterase ([C]), glycosyltransferase 36 ([G]), and branched-amino acid transporter ([E]). All correspond to different biological pathways

⁴ Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

⁵ Department of Genomics and Health, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain
⁶ Biomedical Research Networking Centre for Epidemiology

and Public Health (CIBERESP), Madrid, Spain ⁷ Spanish National Research Council (CSIC), Institute for Integrative Systems Biology (I2SysBio), University of Valencia, Valencia, Spain

⁸ Department of Endocrinology and Nutrition, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain

⁹ Endocrinology and Nutrition Department, Institute Research and Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain ¹⁰ Department of Endocrinology and Nutrition, L'Hospitalet de Llobregat, Bellvitge University-IDIBELL, Barcelona, Spain

Correspondence

Joan Vendrell and Sonia Fernández-Veledo, Research Unit, University Hospital of Tarragona Joan XXIII, c/ Dr.Mallafré Guasch, 4, 43007 Tarragona. Spain. Email: jvo@comt.es; sonia.fernandez@iispv.cat; sonia.fernandezveledo@gmail.com

ORCID

M-Mar Rodríguez-Peña https://orcid.org/0000-0003-2553-9769

Brenno Astiarraga D https://orcid.org/0000-0003-2216-8974

Jesus Seco b https://orcid.org/0000-0002-4049-8873 *Victoria Ceperuelo-Mallafré* https://orcid.org/0000-0002-4460-9761

Ana Megía https://orcid.org/0000-0002-5101-9452 Sonia Fernández-Veledo https://orcid.org/0000-0003-2906-3788

Joan Vendrell D https://orcid.org/0000-0002-6994-6115

REFERENCES

- 1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab.* 2018;27(4):740-756. https://doi.org/10.1016/j.cmet.2018.03.001.
- Guan X. The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. *Am. J Physiol.* 2014;307(6):R585-R596. https://doi.org/10.1152/ajpregu. 00096.2014.
- 3. Carr RD, Larsen MO, Jelic K, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. *J Clin Endocrinol Metab.* 2010;95(2):872-878. https://doi.org/10.1210/jc.2009-2054.
- Greiner TU, Bäckhed F. Microbial regulation of GLP-1 and L-cell biology. *Mol Metab.* 2016;5(9):753-758. https://doi.org/10.1016/j. molmet.2016.05.012.
- Seganfredo FB, Blume CA, Moehlecke M, et al. Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. *Obes Rev.* 2017;18(8):832-851. https://doi.org/10.1111/obr.12541.
- Pataky Z, Genton L, Spahr L, et al. Impact of hypocaloric hyperproteic diet on gut microbiota in overweight or obese patients with nonalcoholic fatty liver disease: a pilot study. *Dig Dis Sci*. 2016;61(9):2721-2731. https://doi.org/10.1007/s10620-016-4179-1.
- Louis S, Tappu RM, Damms-Machado A, Huson DH, Bischoff SC. Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. *PLoS One.* 2016;11(2). https: //doi.org/10.1371/journal.pone.0149564.
- Paulson JN, Colin Stine O, Bravo HC, Pop M. Differential abundance analysis for microbial marker-gene surveys. *Nat Methods*. 2013;10(12):1200-1202. https://doi.org/10.1038/nmeth.2658.
- Zhang C, Zhang M, Wang S, et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. *ISME J*. 2010;4(2):232-241. https: //doi.org/10.1038/ismej.2009.112.
- Healey GR, Murphy R, Brough L, Butts CA, Coad J. Interindividual variability in gut microbiota and host response to dietary interventions. *Nutr Rev.* 2017;75(12):1059-1080. https://doi.org/ 10.1093/nutrit/nux062.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.